Canaccord Genuity Group Issues Positive Forecast for Privia Health Group (NASDAQ:PRVA) Stock Price

Privia Health Group (NASDAQ:PRVA) had its target price boosted by Canaccord Genuity Group from $32.00 to $33.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also recently weighed in on PRVA. Weiss Ratings reissued a “hold (c)” rating on shares of Privia Health Group in a report on Tuesday, September 29th. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler increased their target price on Privia Health Group from $36.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.25.

Privia Health Group Trading Up 2.0%

NASDAQ PRVA traded up $0.48 on Friday, hitting $24.42. 2,807,727 shares of the company were exchanged, compared to its average volume of 1,143,537. The company has a market cap of $3.12 billion, a P/E ratio of 93.93 and a beta of 0.76. Privia Health Group has a 1-year low of $18.92 and a 1-year high of $28.82. The firm has a 50 day moving average of $21.04 and a two-hundred day moving average of $22.64.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.12. The firm had revenue of $656.96 million for the quarter, compared to the consensus estimate of $610.72 million. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%. The business’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 EPS. Research analysts anticipate that Privia Health Group will post 0.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Privia Health Group during the 2nd quarter worth approximately $550,684,000. Rubicon Founders LLC acquired a new position in Privia Health Group during the second quarter worth $153,635,863. Bank of New York Mellon Corp bought a new position in Privia Health Group in the second quarter valued at $74,425,000. Wellington Management Group LLP grew its position in Privia Health Group by 850.6% in the second quarter. Wellington Management Group LLP now owns 2,130,289 shares of the company’s stock valued at $54,812,000 after purchasing an additional 1,906,187 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in Privia Health Group in the second quarter valued at $36,848,000. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia reported Q3 earnings of $0.21 per share, above the $0.09 consensus estimate, and revenue of $656.96 million versus expectations of $610.72 million. Revenue rose 13.2% year over year. Privia Health Q3 results
• Positive Sentiment: The company raised full-year 2026 guidance across all key financial metrics. Year-to-date adjusted EBITDA was $114.7 million, up 21.9% from the same period in 2025, supporting the improved outlook. Privia Health Q3 results
• Positive Sentiment: Canaccord Genuity raised its price target from $32 to $33 and maintained a Buy rating. Piper Sandler raised its target from $36 to $38 and kept an Overweight rating, signaling increased analyst confidence. Canaccord Genuity price-target update Piper Sandler ratings
• Positive Sentiment: A valuation analysis argued that PRVA could be undervalued following its earnings beat, adding to the positive post-results narrative. Privia Health valuation analysis
• Negative Sentiment: Despite beating estimates, reported quarterly EPS of $0.21 was below the $0.29 reported a year earlier, a potential caveat for investors weighing the strong revenue growth and raised guidance.

Privia Health Group Company Profile

Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.

Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.